Handa Oncology, LLC

Kc Sung

Fang-Yu Liu

Yu Zhang

George Kraft

John Duan

Shang Wei Qin

Chi-Cheng Lin

Chin-Yao Yang

Yi-Hsin Lin

Li Qiao

The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.

Cabozantinib compositions and methods of use

The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associated with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts. The present invention further relates to polymorphic forms of cabozantinib lauryl sulfate salts, methods for preparing the polymorphic forms and uses thereof.

The present invention relates to kinase inhibitor C-Caliphatic sulfate salts, compositions containing kinase inhibitor C-Caliphatic sulfate salts and uses thereof.

Kinase inhibitor salts, and compositions thereof

Growing community of inventors

Tainan, Taiwan

Kc Sung